Search results
Added:
1 year ago
Added:
2 years ago
EASD 2023 – Dr Carl G Streed (Boston University School of Medicine, US) joins us to summarise healthcare disparities among the LGBTQ+ population.In this interview, Dr Streed discusses the available evidence and explains the minority stress model. This model suggests that experiences of discrimination and stress contribute to worse health outcomes in the LGBTQ community. This can lead to mental…
View more
Added:
1 month ago
Source:
Radcliffe Cardiology, Mirjam Boros
The global burden of heart failure (HF) remains a significant challenge for healthcare systems.² While clinical risk factors are well-established, the utility of genetic information in predicting incident HF has been less certain. A recent study investigated the ability of a heart failure polygenic risk score (HF PRS) to predict new-onset HF in individuals across the full spectrum of…
View more
Added:
1 month ago
EASD Congress 2025 - Dr Camilla Andersen (The University of Western Australia, Perth, AU) joins us to discuss findings from the EMPIRE-PREVENT: Metabolic study, investigating the metabolic effects of empagliflozin in elderly and obese patients at high risk of developing heart failure (HF).This randomized controlled trial evaluated 165 patients aged 60–84 years with obesity (BMI >28kg/m²) and…
View more
Added:
1 month ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type…
View more
Increased Systolic Blood Pressure Variability Over Time Linked to Higher Risk of CVD, CKD, and Death
Added:
3 months ago
Source:
Radcliffe CVRM
News
Added:
5 months ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure…
View more
Added:
2 years ago
ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
23 Jun 2025 – Buckinghamshire, UKRadcliffe Group is delighted to report strong Impact Factor growth across its journals in the latest Journal Citation Reports™ (2024) from Clarivate™. This progress highlights the strength and influence of Radcliffe’s cardiovascular portfolio, made possible by the dedicated efforts of its editorial teams, authors, and reviewers.Cardiac Failure Review (CFR), under…
View more
Added:
3 months ago
Source:
Radcliffe Cardiology
With global temperatures rising and heatwaves becoming more frequent and intense, the impact on public health is a growing concern. A new scientific statement from the European Society of Cardiology (ESC) and several of its constituent bodies highlights the significant risk that extreme heat poses to cardiovascular health, particularly for the elderly and individuals with pre-existing…
View more